Sabby Management, LLC Akari Therapeutics PLC Transaction History

Sabby Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.84 $39,382 - $54,009	-14,065 Reduced 7.9%	164,026 $511,000
Q3 2023 Nov 14, 2023	SELL	$0.17 - $4.08 $1.23 Million - $29.4 Million	-7,214,040 Reduced 97.59%	178,091 $703,000
Q2 2023 Aug 14, 2023	SELL	$0.16 - $0.22 $87,957 - $120,941	-549,736 Reduced 6.92%	7,392,131 $1.26 Million
Q1 2023 May 15, 2023	BUY	$0.15 - $0.54 $641,029 - $2.31 Million	4,273,528 Added 116.5%	7,941,867 $1.43 Million
Q4 2022 Feb 14, 2023	SELL	$0.41 - $12.8 $178,251 - $5.56 Million	-434,759 Reduced 10.6%	3,668,339 $1.72 Million
Q3 2022 Nov 14, 2022	BUY	$0.6 - $12.6 $2.46 Million - $51.7 Million	4,103,098 New	4,103,098 $2.59 Million

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $164M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.